| NCT06710756 | Lead-212 PSV359 Therapy for Patients With Solid Tumors | RECRUITING | PHASE1, PHASE2 | 2025-04-28 | 2032-05-28 | 2028-01-31 |
| NCT05636618 | Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors | RECRUITING | PHASE1, PHASE2 | 2023-09-27 | 2029-12-26 | 2029-11-26 |
| NCT05655312 | MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma | RECRUITING | PHASE1, PHASE2 | 2023-06-01 | 2029-12-31 | 2027-12-31 |
| NCT04904120 | Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy | COMPLETED | PHASE1 | 2021-03-05 | 2022-09-20 | 2022-09-20 |